Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Narjust Duma

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Clinical Lung Cancer|May 25, 2022
Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancerSteven E Schild, Xiaofei Wang, Christine M Bestvina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2019
Evaluating Unconscious Bias: Speaker Introductions at an International Oncology ConferenceNarjust Duma, Urshila Durani, Cynthia B Woods, et al.
The Oncologist|November 11, 2018
Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical TrialsNarjust Duma, Sejal M Kothadia, Tariq U Azam, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 13, 2018
Adherence to Guidelines for Breast Surveillance in Breast Cancer SurvivorsKathryn J Ruddy, Lindsey Sangaralingham, Rachel A Freedman, et al.
JAMA Oncology|September 2, 2021
COVID-19 and Cancer: A Review of the Registry-Based Pandemic ResponseAakash Desai, Turab J Mohammed, Narjust Duma, et al.
Cancer|October 8, 2019
Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st centurySiddhartha Yadav, Dhauna Karam, Irbaz Bin Riaz, et al.
The American Journal of Medicine|April 28, 2022
Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor TrialsIrbaz B Riaz, Mahnoor Islam, Ahsan Masood Khan, et al.
The Oncologist|May 1, 2019
Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?Narjust Duma, Azzouqa Abdel-Ghani, Siddhartha Yadav, et al.
JAMA Oncology|April 26, 2019
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysisYucai Wang, Shouhao Zhou, Fang Yang, et al.
American Journal of Respiratory and Critical Care Medicine|March 15, 2023
Research Priorities for Interventions to Address Health Disparities in Lung Nodule Management: An Official American Thoracic Society Research StatementKatrina Steiling, Hasmeena Kathuria, Chidiebere Peter Echieh, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Clinical Lung Cancer|May 25, 2022
Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancerSteven E Schild, Xiaofei Wang, Christine M Bestvina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2019
Evaluating Unconscious Bias: Speaker Introductions at an International Oncology ConferenceNarjust Duma, Urshila Durani, Cynthia B Woods, et al.
The Oncologist|November 11, 2018
Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical TrialsNarjust Duma, Sejal M Kothadia, Tariq U Azam, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 13, 2018
Adherence to Guidelines for Breast Surveillance in Breast Cancer SurvivorsKathryn J Ruddy, Lindsey Sangaralingham, Rachel A Freedman, et al.
JAMA Oncology|September 2, 2021
COVID-19 and Cancer: A Review of the Registry-Based Pandemic ResponseAakash Desai, Turab J Mohammed, Narjust Duma, et al.
Cancer|October 8, 2019
Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st centurySiddhartha Yadav, Dhauna Karam, Irbaz Bin Riaz, et al.
The American Journal of Medicine|April 28, 2022
Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor TrialsIrbaz B Riaz, Mahnoor Islam, Ahsan Masood Khan, et al.
The Oncologist|May 1, 2019
Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?Narjust Duma, Azzouqa Abdel-Ghani, Siddhartha Yadav, et al.
JAMA Oncology|April 26, 2019
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysisYucai Wang, Shouhao Zhou, Fang Yang, et al.
American Journal of Respiratory and Critical Care Medicine|March 15, 2023
Research Priorities for Interventions to Address Health Disparities in Lung Nodule Management: An Official American Thoracic Society Research StatementKatrina Steiling, Hasmeena Kathuria, Chidiebere Peter Echieh, et al.
Pageof 6